Optimizing Melphalan dose among older adults with Multiple Myeloma receiving Autologous Stem Cell Transplantation

Description

This research project focuses on optimizing melphalan dosing for older adults undergoing autologous stem cell transplantation (ASCT) for multiple myeloma (MM). While ASCT with high-dose melphalan is effective, older adults are at increased risk of severe toxicities, impacting their quality of life. Currently, there’s uncertainty about the appropriate melphalan dose for older adults, with many opting for reduced doses due to concerns about toxicity. However, this approach lacks sufficient evidence and leads to wide variability in melphalan exposure, which can result in unnecessary toxicities. The study aims to address this by developing strategies to individualize melphalan dosing, aiming to minimize toxicity while maintaining treatment efficacy. This research seeks to provide much-needed guidance for optimizing ASCT in older adults with MM, ultimately improving patient outcomes and quality of life.